BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 219469)

  • 1. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme].
    Waeber B; Gavras H; Brunner HR; Chappuis P; Turini GA
    Schweiz Med Wochenschr; 1978 Dec; 108(49):1981-3. PubMed ID: 219469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
    Larochelle P; Genest J; Kuchel O; Boucher R; Gutkowska Y; McKinstry D
    Can Med Assoc J; 1979 Aug; 121(3):309-16. PubMed ID: 223756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.
    Holtzman E; Rosenthal T; Stern N; Knecht A; Yaron A
    Isr J Med Sci; 1982 May; 18(5):597-602. PubMed ID: 6284678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
    Bing RF; Russell GI; Swales JD; Thurston H
    J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of angiotensin I converting enzyme inhibitor (SQ 14225) on arterial blood pressure].
    Watanabe H
    Nihon Jinzo Gakkai Shi; 1982 Apr; 24(4):405-19. PubMed ID: 6750185
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II].
    Schalekamp MA; de Bruyn JH; Wenting GJ; Man in 't Veld AJ; Derkx FH
    Ned Tijdschr Geneeskd; 1980 Nov; 124(47):1996-2003. PubMed ID: 6255350
    [No Abstract]   [Full Text] [Related]  

  • 7. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of the angiotensin I converting enzyme with SQ-14225 (captopril) in the medical treatment of severe renovascular hypertension].
    Martínez Amenós A; Caralps A; Rama H; Sarrias X; Alsina J
    Rev Clin Esp; 1981 Sep; 162(6):265-8. PubMed ID: 7036249
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of severe arterial hypertension with captopril (SQ 14.225) (author's transl)].
    Di Giulio S; Perez-Ramirez JL; Jamoun P; Grünfeld JP; Meyer P
    Nouv Presse Med; 1981 Apr; 10(19):1551-5. PubMed ID: 6269557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of captopril on the development of tolerance to guanethidine.
    Rankin GO; Haas GJ
    Fed Proc; 1984 Apr; 43(5):1342-5. PubMed ID: 6323227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with a new antihypertensive drug (captopril SQ 14.225), an oral inhibitor of converting enzyme].
    Santucci A; Aguglia F; Ficara C
    Clin Ter; 1981 Apr; 97(1):43-58. PubMed ID: 6269793
    [No Abstract]   [Full Text] [Related]  

  • 12. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with the angiotensin converting enzyme inhibitor captopril.
    Walter NM; Whitworth JA; Kincaid-Smith P
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():117-21. PubMed ID: 6291829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Captopril and salt subtraction to treat "uncontrollable" hypertension in haemodialysis patients.
    Wauters JP; Waeber B; Brunner HR; Turini GA; Guignard JP; Gavras H
    Proc Eur Dial Transplant Assoc; 1979; 16():610-7. PubMed ID: 232915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension.
    Zweifler AJ; Julius S; Nicholls MG
    Arch Intern Med; 1981 Jun; 141(7):907-10. PubMed ID: 6263204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics.
    Chan PS; Ronsberg MA; Cervoni P
    Fed Proc; 1984 Apr; 43(5):1346-50. PubMed ID: 6200364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with converting-enzyme inhibitors in hypertension.
    Weber MA
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):45-51. PubMed ID: 3037889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor.
    Brunner HR; Gavras H; Turini GA; Waeber B; Cappuis P; McKinstry DN
    Clin Sci Mol Med Suppl; 1978 Dec; 4():293s-295s. PubMed ID: 215374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long term treatment of resistant hypertension with captopril (author's transl)].
    Guedon J; Chaignon M; Lucsko M; Cuche JL; Aubert P; Piete AM
    Nouv Presse Med; 1981 Apr; 10(19):1565-9. PubMed ID: 7025846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin converting enzyme--captopril].
    Kaneko Y; Shionoiri H; Uneda S; Fujishima S
    Nihon Rinsho; 1979 Oct; 37(10):3492-8. PubMed ID: 392136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.